News
LBRX
44.63
-3.50%
-1.62
Weekly Report: what happened at LBRX last week (0831-0904)?
Weekly Report · 4d ago
LB Pharmaceuticals Names Joseph Miller Chief Financial Officer
Dow Jones · 09/03 12:43
LB Pharmaceuticals Appoints Joseph Miller CFO
Benzinga · 09/03 12:07
Press Release: LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
Dow Jones · 09/03 12:00
Weekly Report: what happened at LBRX last week (0824-0828)?
Weekly Report · 08/31 09:49
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 08/24 13:30
LB Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/24 10:16
LB Pharmaceuticals Price Target Raised to $60.00/Share From $45.00 by HC Wainwright & Co.
Dow Jones · 08/24 10:16
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60
Benzinga · 08/24 10:06
LB Pharmaceuticals price target raised to $60 from $45 at H.C. Wainwright
TipRanks · 08/24 10:05
Weekly Report: what happened at LBRX last week (0817-0821)?
Weekly Report · 08/24 09:49
LB Pharmaceuticals price target raised to $69 from $45 at Clear Street
TipRanks · 08/20 20:15
Weekly Report: what happened at LBRX last week (0810-0814)?
Weekly Report · 08/17 09:50
LB Pharmaceuticals price target raised to $53 from $40 at Stifel
TipRanks · 08/17 08:06
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Seeking Alpha · 08/17 02:54
Craig-Hallum Remains a Buy on LB Pharmaceuticals, Inc. (LBRX)
TipRanks · 08/12 13:36
LB Pharmaceuticals Price Target Raised to $54.00/Share From $46.00 by BMO Capital
Dow Jones · 08/12 12:15
LB Pharmaceuticals Is Maintained at Outperform by BMO Capital
Dow Jones · 08/12 12:15
BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54
Benzinga · 08/12 12:05
LB Pharmaceuticals Accelerates LB-102 Schizophrenia Program; Phase 3 Data Expected In 1H27
NASDAQ · 08/11 17:55
More
Webull provides a variety of real-time LBRX stock news. You can receive the latest news about LB Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About LBRX
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.